Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan.
Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan
Kardiol Pol. 2020 Aug 25;78(7-8):667-673. doi: 10.33963/KP.15493. Epub 2020 Jul 7.
Antiplatelet therapy is the mainstay preventive strategy for cardiovascular diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is the standard treatment for patients who underwent percutaneous coronary intervention. The Total Thrombus‑Formation Analysis System (T‑TAS) is a microchip flow‑chamber system developed to evaluate overall thrombus formation under flow conditions, which is reportedly able to assess single and combined antithrombotic therapy. Here, we focus on this new system, T‑TAS, and review its characteristics together with those of the conventional systems available for evaluation of antithrombotic therapies for cardiovascular diseases.
抗血小板治疗是心血管疾病的主要预防策略，双联抗血小板治疗包括阿司匹林和 P2Y12 抑制剂，是经皮冠状动脉介入治疗患者的标准治疗方法。全血栓形成分析系统（T-TAS）是一种微芯片流动室系统，用于评估流动条件下的整体血栓形成，据报道，该系统能够评估单一和联合抗血栓治疗。在这里，我们重点介绍这个新系统 T-TAS，并结合用于评估心血管疾病抗血栓治疗的常规系统，一起回顾其特点。
